Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 6, 2009

Quidel and BioHelix Join Forces to Develop Handheld Tests for Pathogens

  • Quidel will be developing in vitro molecular diagnostic tests utilizing BioHelix’ isothermal-amplification technology. BioHelix’ expertise in the R&D of nucleic acid technologies for diagnostic applications will be combined with Quidel’s strength in the development, manufacture, and commercialization of such tests.

    Under the development and commercialization agreement, Quidel will fund and jointly develop with BioHelix assays for rapid detection of infectious pathogens in a noninstrumented, handheld format. BioHelix will have primary responsibility for assay development. Quidel will have exclusive, worldwide commercialization rights for the new products. It will also undertake all manufacturing and marketing.

    BioHelix’ IsoAmp® Molecular Analyzer is an instrument-free molecular diagnostic platform consisting of its Helicase-Dependent Amplification technology and a disposable detection device entitled the BESt™ Cassette.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »